BANK VONTOBEL/CALL/VERTEX PHARMACEUTICALS/370/0.1/21.06.24 | Delayed Deutsche Boerse AG 08:13:09 03/06/2024 pm IST | ||
| 9.07 EUR | +19.34% |
|
| 1 month | +137.50% | ||
| 3 months | +21.02% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 03/24/03 | 9.07 | +19.34% |
| 31/24/31 | 7.6 | +14.80% |
| 30/24/30 | 6.62 | -4.47% |
| 29/24/29 | 6.93 | -4.94% |
| 28/24/28 | 7.29 | -14.64% |
Delayed Quote Deutsche Boerse AG
Last update June 03, 2024 at 08:13 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
Vontobel
|
| WKN | VM3RNB |
| ISIN | DE000VM3RNB7 |
| Date issued | 09/10/2023 |
| Strike | 370 $ |
| Maturity | 21/06/2024 (18 Days) |
| Parity | 10 : 1 |
| Emission price | 3.37 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 9.07 € |
|---|---|
| Lowest since issue | 2.17 € |
| Spread | 0.04 € |
| Spread % | 0.44% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
455.3
USD
Average target price
463.5
USD
Spread / Average Target
+1.80%
- Stock Market
- Warrants
- Warrant
